表皮生长因子受体与放射敏感性关系的研究进展

doi:10.11904/j.issn.1002-3070.2016.03.017

Abstract

Abstract: In recent years,treatment which targeting abnormal biological activity in oncogenesis and tumor progression developed with better understanding of the mechanism of oncogenesis and general progress in molecular biology.Studies have indicated that targeting drugs can inhibit the activity of tumor growth,and has a synergistic effect with radiotherapy or chemotherapy.Combined treatment with chemotherapy and radiotherapy is often used to treat a variety of tumors.However,the application of the combined treatment has been limited by its significant toxic and side effects.The emergence of targeting therapy enabled a new strategy in the treatment of malignant tumors with its combination with radiotherapy.Epidermal growth factor receptor(EGFR)is the most widely researched and applied target of targeting drugs.This review discusses the combined treatment of EGFR-targeting drugs and radiotherapy,and the relationship between EGFR and radio-sensitivity.

Key words: Target therapy, Radiotherapy, Epidermal growth factor receptor, Radiosensitity

CLC Number:

R734.2

LIU Wei,LI Huiyan. Progress in relationship between epidermal growth factor receptor and radiosensitivity[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(3): 275-278.

References

1 Rysman B,Mouawad F,Gros A,et al.Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas[J].Head Neck,2016.[Epub ahead of print]
2 Liu J,Hu J,Cheng L,et al.Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS[J].Onco Targets Ther,2016,9(3):557-565.
3 Chi A,Remick S,Tse W.EGFR inhibition in non-small cell lung cancer:current evidence and future directions[J].Biomark Res,2013,1(1):2-12.
4 Wang C,Fu X,Cai X,et al.High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy[J].Onco Targets Ther,2015,9:117-122.
5 Huguet F,Fernet M,Giocanti N,et al.Afatinib,an irreversible EGFR family inhibitor,shows activity toward pancreatic cancer cells,alone and in combination with radiotherapy,independent of KRAS status[J].Target Oncol,2015.[Epub ahead of print]
6 Raymond E,Faivre S,Armand JP.Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy[J].Drugs,2000,60(suppl 1):15-23.
7 Liu W,Kang M,Qin Y,et al.Apoptosis-inducing effects of cetuximab combined with radiotherapy and hypothermia on human nasopharyngeal carcinoma CNE cells[J].Int J Clin Exp Med,2015,8(2):2182-2189.
8 Tsai YC,Ho PY,Tzen KY,et al.Synergistic blockade of EGFR and HER-2 by new-generation EGFR tyrosine kinase inhibitor enhances radiation effect in bladder cancer cells[J].Mol Cancer Ther,2015,14(3):810-820.
9 Huang SM,Harari PM.Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas:inhibition of damage repair,cell cycle kinetics,and tumor angiogenesis[J].Clin Cancer Res,2000,6(6):2166-2174.
10 Park HJ,Oh JS,Chang JW,et al.Proton irradiation sensitizes radioresistant non-small cell lung cancer cells by modulating epidermal growth factor receptor-mediated DNA repair[J].Anticancer Res,2016,36(1):205-212.
11 Zhong X,Luo G,Zhou X,et al.Rad51 in regulating the radiosensitivity of non-small cell lung cancer with different epidermal growth factor receptor mutation status[J].Thorac Cancer,2016,7(1):50-60.
12 Maseki S,Ijichi K,Nakanishi H,et al.Efficacy of gemcitabine and combination treatment in head and neck squamous cell carcinoma[J].Mol Clin Oncol,2013,1(5):918-924.
13 Huang SM,Harari PM,Li J,et al.Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839(Iressa)[J].Clin Cancer Res,2002,62(15):4300-4306.
14 Bhardwaj B,Revannasiddaiah S,Bhardwaj H,et al.Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma[J].Ann Transl Med,2016,4(3):50-58.
15 Niyaz M,Anwer J,Liu H,et al.Characterization of the expression and clinical features of epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in esophageal carcinoma[J].Oncol Lett,2015,10(6):3696-3704.
16 Bonner JA,Harari PM,Giralt J,et al.Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer:5-year survival data from aphase 3 randomised trial,and relation between cetuximab-induced rash and survival[J].Lancet Oncol,2010,11(1):21-28.
17 Provencio M,Sanchez A.Therapeutic integration of new molecule-targeted therapies with radiotherapy in lung cancer[J].Transl Lung Cancer Res,2014,3(2):89-94.

[1]	LI Jiaqi,LUAN Jinwei,ZHANG Yu,LI Xianglan. Analysis of clinicopathological features,recurrence and metastasis in 763 triple-negative breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 244-249.
[2]	LI Shan,ZHAO Chunbo,QIAO Wenbo. Progress in the application of intraoperative radiotherapy in pancreatic cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 280-283.
[3]	FENG Yue,XING Linan,WANG Zhao,ZHANG Yunyan. Correlation between NLR and prognosis of concurrent chemoradiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 284-288.
[4]	ZHANG Pan, ZHANG Di, DAI Xiaobo. Advanced in re-radiotherapy for recurrent nasopharyngeal carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 92-96.
[5]	LI Yue, XU Ke, HAN Zengxiang, SUN Min, FAN Guohua, ZHANG Yong. Advances in the role of tumor-associated macrophage in colon cancer and targeted therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 450-454.
[6]	YAN Shi, HUO Mingming, PANG Hui, LI Yan, CAI Li. Effects of p53 on predictive value for efficacy of endocrine drugs in postoperative postmenopausal breast cancer patients with HR positive and HER-2 positive [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 234-213.
[7]	DU Yesheng, HU Songliu, XU Xiangying. Study of oligodendrocyte metastasis in non-small cell lung cancer by stereotactic radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 154-158.
[8]	SUN Mingliang, XU Jianyu, XU Xiangying. Stereotactic radiotherapy for early stage of non - small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 53-56.
[9]	LIU Guohui, GU Anxin, YIN Hongtao, CAO Yang, HE Yunlong, WANG Chunbo, E Mingyan. Protosappanin A increases the sensitivity of gastric cancer SGC-7901 cells to radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 500-505.
[10]	ZHAO Yongrui, XU Jiankun. The application of PET/MRI in high-grade glioma by radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 564-568.
[11]	LUO Jianing, HAO Chuncheng, ZHANG Jianxin, LU Jiangyue, GE Xiaofeng. Effect of postoperative adjuvant radiotherapy on prognosis of triple-negative breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 411-416.
[12]	HUANG Chenglu, HAN Shaohui, XU Suqin, ZHAO Jungang. The research progress of primary pulmonary mucinous adenocarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 463-467.
[13]	CHENG Jing,CHEN Ji,WANG Xiaoyong,ZHANG Junhong,ZHOU Fuxiang,XIE Conghua. Changes in the volume of chest muscles and its clinical significance in thoracic radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 123-130.
[14]	QU Yuanyuan,XU Xiangying,ZHUANG Ming,YIN Hongtao,HU Songliu,WANG Chunbo,CAO Yang. Nimotuzumab enhances the radiosensitivity of lung cancer A549 cells in vitro [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 497-501.
[15]	ZHAO Xiangxuan, WEN Feng, MAO Xiaonan, LU Zaiming. Study advances on the roles of apoptosis in hepatocellular carcinoma therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 448-452.

Progress in relationship between epidermal growth factor receptor and radiosensitivity

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments